[Systemic lupus erythematosus with disease onset after age 65]

Rev Med Interne. 2003 May;24(5):288-94. doi: 10.1016/s0248-8663(03)00052-3.
[Article in French]

Abstract

Objectives: Systemic lupus erythematosus with disease-onset in the elderly has rarely been studied (only one report about 21 patients with disease onset at 65 and older). Is the management of this pathology modified in this population?

Methods: Seventeen hospitalised cases of lupus patients with disease onset at 65 or older are retrospectively reported between 1988 and 2000. The results are compared with those of younger subjects.

Results: The female to male ratio is 1.83. Mean age at disease onset is 71.9 +/- 3.5 years. Mean duration of follow-up is 3.5 +/- 2.4 years. Main initial symptoms are: deterioration of general status (41%), arthritis (35%), cutaneous manifestations (35%), thrombo-embolism (24%) and pleuritis (18%). Malar rash is uncommon (12%). Nephropathy is never a revealing symptom and is rarely serious during the disease's evolution. Like in neurologic manifestations, the etiology has to be discussed in relation to associated co-morbidities. Concerning haematologic features, lymphopenia is found in 82% of the cases with a questionable specificity. Antinuclear antibodies are constant, anti-dsDNA antibodies are found in 82% of the cases, antibodies to extractable nuclear antigens in 50%, and anticoagulant circulating activity in 59%. Prognosis is difficult to assess in such a limited series but 5-years survival probability is 83%. Glucocorticoid lead to 50% of major complications.

Conclusions: This study focuses on the particular initial manifestations of systemic lupus erythematosus in the elderly (deterioration of general status, thrombosis, unusual cutaneous symptoms), and on the specificity of differential diagnosis and treatment.

Publication types

  • English Abstract

MeSH terms

  • Age Distribution
  • Age of Onset
  • Aged
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Antinuclear / blood
  • Antigens, Nuclear / immunology
  • Comorbidity
  • Diagnosis, Differential
  • Female
  • France / epidemiology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Incidence
  • Lupus Erythematosus, Systemic / diagnosis*
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / epidemiology
  • Lupus Erythematosus, Systemic / etiology
  • Male
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Factors
  • Sex Distribution
  • Steroids
  • Survival Analysis
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Antinuclear
  • Antigens, Nuclear
  • Immunosuppressive Agents
  • Steroids